Landscape of KRAS(G12C), Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers

Promising single-agent activity from sotorasib and adagrasib in KRAS(G12C)-mutant tumors has provided clinical evidence of effective KRAS signaling inhibition. However, comprehensive analysis of KRAS-variant prevalence, genomic alterations, and the relationship between KRAS and immuno-oncology bioma...

Descripción completa

Detalles Bibliográficos
Autores principales: Salem, Mohamed E., El-Refai, Sherif M., Sha, Wei, Puccini, Alberto, Grothey, Axel, George, Thomas J., Hwang, Jimmy J., O'Neil, Bert, Barrett, Alexander S., Kadakia, Kunal C., Musselwhite, Laura W., Raghavan, Derek, Van Cutsem, Eric, Tabernero, Josep, Tie, Jeanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966967/
https://www.ncbi.nlm.nih.gov/pubmed/35319967
http://dx.doi.org/10.1200/PO.21.00245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966967/
https://www.ncbi.nlm.nih.gov/pubmed/35319967
http://dx.doi.org/10.1200/PO.21.00245

Ejemplares similares